CR4056   Click here for help

GtoPdb Ligand ID: 10453

Synonyms: CR-4056 | US8633208, 1
Compound class: Synthetic organic
Comment: CR4056 is reported to bind imidazoline-binding sites known as imidazoline receptor I2 [2]. It was developed by Rottapharm Biotech and is being pursued as a novel analgesic for inflammatory and neuropathic pain [1,3-4]. Potential for efficacy in humans has been demonstrated in rodent models of nociceptive and neuropathic pain. To date (August 2019) clinical efficacy from a proof-of-concept study in patients with knee osteoarthritis pain has only been reported in meeting abstract form (see Rovati et al. Abstract Number: 1193, 2017 ACR/ARHP Annual Meeting). The associated trial registry number is EudraCT 2015-001136-37.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 3
Hydrogen bond donors 0
Rotatable bonds 2
Topological polar surface area 43.08
Molecular weight 272.11
XLogP 2.92
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES c1ccc(cc1)c1ncc2c(n1)ccc(c2)n1cncc1
Isomeric SMILES c1ccc(cc1)c1ncc2c(n1)ccc(c2)n1cncc1
InChI InChI=1S/C17H12N4/c1-2-4-13(5-3-1)17-19-11-14-10-15(6-7-16(14)20-17)21-9-8-18-12-21/h1-12H
InChI Key CSZGXYBGYFNSCO-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
CR4056 has advanced to Phase 2 evaluation as a first-in-class imidazoline-2 (I2) receptor ligand for the treatment of pain associated with osteoarthritis.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
I2 receptor ligands modulate the enzymatic activity of monoamine oxidases (MAO) to mediate inhibition of noradrenergic (descending) pain pathways [3].